150 mg daily for a month then 300 mg daily for the rest of the study (5 months)

Musculoskeletal Degeneration

Inflammation

Hyperuricemia

Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.
Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant.

Allopurinol Pill

Instituto Nacional de Cardiología

National Institute of Cardiology Mexico

Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms

Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept

To measure changes in proinflammatory cytokines (Interleukin 1ß (IL-1ß))

To measure changes in proinflammatory cytokines (Tumor Necrosis Factor)

To measure changes in proinflammatory cytokines (Interleukin 6 (IL-6))

To measure changes in proinflammatory cytokines (Interferon-γ)

To measure changes in proinflammatory cytokines (Interleukin 18 (IL-18))

To measure changes in proinflammatory cytokines (Interleukin 17 (IL-17))

To measure changes in chemokines (Interleukin 8 (IL-8))

To measure changes in chemokines (monocyte chemoattractant protein 1 (MCP-1))

To measure changes in microRNAs (miR) (miR-155)

To measure changes in the percentage of Cluster of Differentiation 4 cells that lack the expression of Cluster of Differentiation 28 (CD4+CD28null)

Presence of the ultrasonographic elemental lesions caused by monosodium urate crystals: (Double contour sign is a hyperechoic abnormal band over the superficial margin of articular hyaline cartilage, independent from insonation angle which can be regular or irregular, continuous or intermittent and that distinguishes itself from the cartilage interphase sign)

Presence of the ultrasonographic elemental lesions caused by monosodium urate crystals: (Tophi are described, independent of location, as an heterogenous, circumscript aggregate, hyper- and/or hypoechoic, which can be surrounded by a small anechoic halo and can have a posterior acoustic shadow)

Presence of the ultrasonographic elemental lesions caused by monosodium urate crystals: (Aggregates are described, independent of location, as heterogenous hyperechoic foci which maintain a high degree of reflectivity even when gain is reduced to the minimum or when the insonation angle is changed, also they can sometimes create a posterior acoustic shadow)

Presence of the ultrasonographic elemental lesions caused by monosodium urate crystals: (Erosions are described as a discontinuation of the bone surface, seen in two perpendicular planes)

Luis M Amezcua-Guerra

Head of Immunology Department, Principal Investigator

Instituto Nacional de Cardiologia Ignacio Chavez

Instituto Nacional de Rehabilitacion

Subjects received nasal spray containing both saline+glucose twice daily for 3 months

Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.

Nasal spray with saline+glucose twice daily for 3 months
Saline + glucose: A bag on valve nasal spray device containing isotone saline and 5% glucose

Saline+Glucose Nasal Spray

Nasal spray in a bag-on-valve device with 50U/ml glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
Glucose oxidase: Glucose oxidase is a hydrogen peroxide producing enzyme, imitating the inhibitory effects of the normal bacterial flora of the nasopharynx

Nasal Spray With Glucose Oxidase+Glucose

Total

Sex: Female, Male

Region of Enrollment

Days with upper respiratory tract infection symptoms during a 3 months period are recorded in a home protocol by the parents of the children.

Respiratory Infectious Symptoms

Overall Study

MD, PhD Krister Tano

Upper Respiratory Tract Infections

Placebo

a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.

Glucose oxidase

Öronmottagningen

Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children

Placebo Controlled Study Among Children Below Four Years of Age, Investigating Whether a Glucose Oxidase Nasal Spray Can Reduce Days With Upper Respiratory Tract Infection Symptoms

Krister Tano

MD, PhD

This group will be treated concomitantly with Coenzyme Q10

Treated with capsules containing the vehicle.

Aneuploidy

Pregnancy

Miscarriage

Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment

Coenzyme Q10 concomitant treatment

Treated with capsules containing the vehicle (Sesame oil).

oxidase/karijes

Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms

Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children

The Effect of Co Enzyme Q10 Together With Fertility Drugs on Pregnancy Outcome of in Vitro Fertilization

Mouth Care Regimes During Radiotherapy

Najkompletnija baza ljekovitog bilja potpomognuta znanošću